What is William Blair's Estimate for Korro Bio Q1 Earnings?

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Investment analysts at William Blair issued their Q1 2025 earnings per share estimates for Korro Bio in a research note issued on Tuesday, March 18th. William Blair analyst M. Minter anticipates that the company will earn ($2.91) per share for the quarter. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio's Q2 2025 earnings at ($2.98) EPS, Q3 2025 earnings at ($3.02) EPS, Q4 2025 earnings at ($3.05) EPS, FY2025 earnings at ($11.95) EPS, Q1 2026 earnings at ($3.11) EPS, Q2 2026 earnings at ($3.14) EPS, Q3 2026 earnings at ($3.17) EPS, Q4 2026 earnings at ($3.20) EPS and FY2026 earnings at ($12.61) EPS.

KRRO has been the subject of several other reports. HC Wainwright reissued a "buy" rating and set a $115.00 price objective on shares of Korro Bio in a research note on Thursday, March 20th. Oppenheimer assumed coverage on Korro Bio in a research report on Friday, January 10th. They set an "outperform" rating and a $155.00 price target for the company. Finally, Royal Bank of Canada cut their price objective on Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a report on Wednesday, March 19th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $142.57.

Korro Bio Price Performance

KRRO stock traded down $3.65 on Friday, hitting $20.38. 93,835 shares of the company were exchanged, compared to its average volume of 87,745. The stock has a market capitalization of $191.35 million, a price-to-earnings ratio of -2.17 and a beta of 2.13. Korro Bio has a twelve month low of $18.50 and a twelve month high of $98.00. The business's fifty day moving average is $29.60 and its two-hundred day moving average is $41.23.

Remove Ads

Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($2.26) EPS for the quarter, beating analysts' consensus estimates of ($2.33) by $0.07. The company had revenue of $2.27 million for the quarter.

Institutional Investors Weigh In On Korro Bio

A number of large investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS acquired a new position in Korro Bio during the 4th quarter worth approximately $53,000. Quest Partners LLC grew its holdings in Korro Bio by 172.1% during the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company's stock valued at $59,000 after purchasing an additional 1,124 shares in the last quarter. AlphaQuest LLC increased its stake in Korro Bio by 23.2% during the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock worth $83,000 after buying an additional 412 shares during the period. Brown Brothers Harriman & Co. lifted its holdings in Korro Bio by 251.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company's stock worth $95,000 after buying an additional 2,041 shares in the last quarter. Finally, Vestcor Inc purchased a new position in Korro Bio in the 3rd quarter valued at about $100,000. Institutional investors and hedge funds own 13.18% of the company's stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).